KR20180052790A - Composition for control of statin side effect with extract of Pinellia ternata, Atractylodes macrocephala, Gastrodia elata, Citrus unshiu peel, Poria cocos, Crataegus pinnatifida, Siegesbeckia pubescens Makino and Coptis japonica Makino - Google Patents

Abstract

The present invention relates to a pharmaceutical composition including an extract of mixed medicinal herbs of Pinellia ternata Breit., Atractylodis Rhizoma alba, Gastrodia elata Blume, dried orange peel, larch agaric, fruits of Crataegus pinnatifida Bunge, Siegesbeckia pubescens Makino, and Coptis japonica Makino and, more specifically, relates to a composition to inhibit one or more selected among renal failure, angina, diabetes, hypertension, hepatotoxicity, and muscular disease, which are side effects induced by statin. According to the present invention, the composition includes an extract of mixed medicinal herb of Pinellia ternata Breit., Atractylodis Rhizoma alba, Gastrodia elata Blume, dried orange peel, larch agaric, fruits of Crataegus pinnatifida Bunge, Siegesbeckia pubescens Makino, and Coptis japonica Makino, thus increasing an amount of Coenzyme Q10, decreasing an amount of angiotensin and angiotensin converting enzyme (ACE), which are a hypertension related marker, and decreasing an amount of aspartate aminotransferase (AST) in blood, thereby providing an effect of inhibiting side effects of statin.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for inhibiting side effects caused by statins, which comprises extracts of a medicinal herb comprising a mixture of a herbicidal, anhydrous, elata, Citrus unshiu peel, Poria cocos, Crataegus pinnatifida, Siegesbeckia pubescens Makino and Coptis japonica Makino}

The present invention relates to an extract of a medicinal substance which is a mixture of semi-summer, white mulberry, chinese mulberry, dermis, bamboo, mountain bamboo, And more particularly to a composition for inhibiting at least one selected from side effects due to statins such as renal failure, angina pectoris, diabetes, hypertension, hepatotoxicity and myopathy.

Statin, a treatment for hyperlipidemia, inhibits the production of cholesterol by interfering with the action of hydroxymethylglutaryl (HMG) -CoA reductase, an enzyme that produces cholesterol in the liver.

However, hydroxymethylglutaryl-CoA reductase is characterized by the production of Coenzyme Q10, an antioxidant that plays an important role in the cardiovascular system. Thus, the long-term use of statins is accompanied by side effects that reduce coenzyme Q10.

Coenzyme Q10 is a potent antioxidant that produces vital energy ATP, protects the heart, and exerts excellent effects on hypertension, renal failure, angina pectoris, and diabetes mellitus, so reduction of coenzyme Q10 can cause a variety of diseases .

Decreased coenzyme Q10 reduces muscle mass and causes muscle wounds to cause muscle soreness. It is commonly known that the pain is in the thighs and calves, and 25% of the pain is caused by systemic pain. In addition to this, it is known to damage the kidneys and liver.

On the other hand, Banha, Baekjung, and Chunma are the main constituents of Baekhaekseongmunmang. It is known that it treats the wind and the license (气虛 证) and shows the digestive efficacy.

It is known that dandelion, bamboo shoot, hanbyeon, japanese, and chrysanthemum have excellent effects on the human body and can be used as medicines. It is not known to inhibit.

Korean Patent Registration No. 10-1350143 (Registration Date: 2014.01.04) discloses a composition for alleviating side effects caused by an anticancer agent comprising an anti-depressant and a herbal extract as an active ingredient. Korean Patent Registration No. 10-1629560 (registered on June, 2016.06.03) discloses an anti-cancer therapeutic agent comprising phospholipase 2 (PLA2), which can prevent or treat adverse reactions caused by an anticancer drug, as an active ingredient Have been described in relation to pharmaceutical compositions.

The present invention aims at developing and providing a composition containing a natural product by inhibiting side effects of statin, which is a therapeutic agent for hyperlipidemia.

In order to accomplish the above object, the present invention provides a method for producing a compound of formula (I) according to any one of (1) to (3), wherein the compound is selected from the group consisting of Half, White, Tenma, Dermis, ), And suppresses adverse effects due to the use of statin.

The food composition of the present invention preferably contains 0.5 to 2 parts by weight, 0.5 to 5 parts by weight, 0.5 to 2 parts by weight of dermis, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight of the extract and 0.5 to 2 parts by weight of the medicinal extract.

On the other hand, in the food composition of the present invention, the extract preferably contains 0.00001 to 90 wt% of the food composition for inhibiting statin adverse effects. When the amount is less than 0.00001% by weight, the effect is insufficient. When the amount is more than 90% by weight, the increase in the effect on the usage amount is insignificant, which is uneconomical.

The present invention also relates to a food composition comprising an anti-obesity extract, an extract of Chrysanthemum horsetail, a chewy gum extract, a dermis extract, a ginseng extract, a horse mackerel extract, a royal jelly extract and a chrysanthemum extract and suppresses adverse effects due to use of statin to provide.

The food composition of the present invention preferably contains 0.5 to 2 parts by weight of an antidote extract, 0.5 to 5 parts by weight of an extract, 0.5 to 2 parts by weight of a dandruff extract, 0.5 to 2 parts by weight of a dandelion extract, 0.5 to 2 parts by weight of a sea tangle extract, 0.5 ~ 2 parts by weight of the extract, 0.5 ~ 2 parts by weight of the extract, and 0.5 ~ 2 parts by weight of the extract.

When the above range is satisfied, the amount of coenzyme Q10 (Coenzyme Q10) of blood is increased, and the amount of angiotensin and angiotensin converting enzyme (ACE), which are hypertension related markers, is decreased, and aspartate aminotransferase (AST ), And thus the statin side effect can be suppressed finally.

Meanwhile, in the food composition of the present invention, the side effect means all the side effects that occur when the statin is administered. For example, the side effect may be one or more selected from renal failure, angina pectoris, diabetes, hypertension, hepatotoxicity and myopathy.

On the other hand, in the food composition of the present invention, the side effect may be due to a decrease in coenzyme Q10 (Coenzyme Q10).

The food composition for inhibiting statin adverse effects of the present invention may be used as a food composition for preventing statin adverse effects such as meat, cereal, common beverages, chocolate, bread, snacks, confectionery, candy, jelly, noodles, gums, dairy products, But the present invention is not limited thereto.

In addition, the present invention relates to a medicament comprising a mixture of semi-summer, white, rhizome, dermis, bamboo, mountain bamboo, And inhibits side effects due to the use of statins.

The pharmaceutical composition of the present invention is preferably 0.5 to 2 parts by weight, 0.5 to 5 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight of the extract and 0.5 to 2 parts by weight of the medicinal extract.

In the pharmaceutical composition of the present invention, the extract is preferably contained in an amount of 0.00001 to 90% by weight relative to the composition. When the amount is less than 0.00001% by weight, the effect is insufficient. When the amount is more than 90% by weight, the increase in the effect on the usage amount is insignificant, which is uneconomical.

The present invention also relates to a pharmaceutical composition comprising an anti-depressant extract, an extract of Chrysanthemum horsetail, a chewing gum extract, a dermatophyte extract, a dicotyledon extract, a horseradish extract, a royal jelly extract and a chrysanthemum extract, and suppresses adverse effects due to the use of statin to provide.

The pharmaceutical composition of the present invention preferably contains 0.5 to 2 parts by weight of an anhydrous extract, 0.5 to 5 parts by weight of an extract, 0.5 to 2 parts by weight of a dandruff extract, 0.5 to 2 parts by weight of an extract of a dandelion extract, 0.5 to 2 parts by weight of a sea tangle extract ~ 2 parts by weight of the extract, 0.5 ~ 2 parts by weight of the extract, and 0.5 ~ 2 parts by weight of the extract.

When the above range is satisfied, the amount of coenzyme Q10 (Coenzyme Q10) is increased in the blood, and the amount of angiotensin and angiotensin converting enzyme (ACE), which are hypertension related markers, is decreased, and hepatocyte enzyme (aspartate aminotransferase, AST), and finally, the side effects of statins can be suppressed.

Meanwhile, in the pharmaceutical composition of the present invention, the side effect refers to all the side effects that occur when the statin is administered. For example, the side effect may be at least one selected from renal failure, angina pectoris, diabetes, hypertension, hepatotoxicity and myopathy.

On the other hand, in the pharmaceutical composition of the present invention, the side effect may be caused by a decrease in coenzyme Q10 (Coenzyme Q10).

In addition, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, diluent or excipient in addition to the active ingredient. Examples of usable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and one or more selected from among them may be used.

In addition, the pharmaceutical composition may further include at least one selected from a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent or an antiseptic agent.

On the other hand, the formulation of the pharmaceutical composition may be in a desired form depending on the method of use, and may be formulated by employing methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal It is good. Examples of specific formulations include, but are not limited to, PLASTERS, GRANULES, LOTIONS, LINIMENTS, LEMONADES, AROMATIC WATERS, POWDERS, SYRUPS, OPHTHALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS, ), Suspensions, DECOCTIONS, INFUSIONS, OPHTHALMIC SOLUTIONS, TABLETS, SUPPOSITORIES, INJECTIONS, SPIRITS, CATAPLSMA, ), Capsules, CREAMS, TROCHES, TINCTURES, PASTES, PILLS, soft or hard gelatin capsules.

On the other hand, the dosage of the pharmaceutical composition of the present invention is preferably determined in consideration of the administration method, the age, sex, weight, and severity of the disease. For example, the pharmaceutical composition of the present invention can be administered at least once at a dose of 0.00001 to 100 mg / kg (body weight) per day based on the active ingredient. However, the dosage is only an example and may be changed by a doctor's prescription depending on the condition of the recipient.

The present invention also provides a pharmaceutical composition for the treatment or prevention of hyperlipidemia comprising statin, wherein the pharmaceutical composition further comprises an extract of a medicinal substance in which the medicinal composition is mixed with an antiperspirant, an extract, a gum, a dermis, And a pharmaceutical composition comprising the same.

The pharmaceutical composition for treating or preventing hyperlipidemia according to the present invention preferably comprises 0.5 to 2 parts by weight, 0.5 to 5 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 0.5 to 2 parts by weight, 2 to about 2 parts by weight of chrysanthemum, and about 0.5 to about 2 parts by weight of chrysanthemum.

Meanwhile, in the pharmaceutical composition for treating or preventing hyperlipidemia according to the present invention, the extract is preferably contained in an amount of 0.00001 to 90% by weight relative to the composition. When the amount is less than 0.00001% by weight, the effect is insufficient. When the amount is more than 90% by weight, the increase in the effect on the usage amount is insignificant, which is uneconomical.

The present invention also provides a pharmaceutical composition for the treatment or prevention of hyperlipidemia comprising statin, wherein the pharmaceutical composition further comprises an anti-depressant extract, an extract of Chrysanthemum hull, an extract of Chimpanzee, a dermis extract, a dormancy extract, a horseradish extract, And a pharmaceutically acceptable carrier.

The pharmaceutical composition for treatment or prevention of hyperlipidemia according to the present invention preferably contains 0.5 to 2 parts by weight of an anhydrous extract, 0.5 to 5 parts by weight of an extract, 0.5 to 2 parts by weight of a dermis extract, 0.5 to 2 parts by weight of an extract 0.5 to 2 parts by weight of an extract of Crassulaceae, 0.5 to 2 parts by weight of a mixture extract and 0.5 to 2 parts by weight of a Crassulaceae extract.

When the above range is satisfied, the amount of coenzyme Q10 (Coenzyme Q10) is increased in the blood, and the amount of angiotensin and angiotensin converting enzyme (ACE), which are hypertension related markers, is decreased, and hepatocyte enzyme (aspartate aminotransferase, AST), so that the statin side effects can be inhibited concurrently with the treatment or prevention of hyperlipidemia.

Meanwhile, in the pharmaceutical composition for the treatment or prevention of hyperlipidemia according to the present invention, the side effect means all the side effects that occur when statin is administered. For example, the side effect is selected from the group consisting of renal failure, angina pectoris, diabetes, hypertension, hepatotoxicity, Or more.

On the other hand, in the pharmaceutical composition for treating or preventing hyperlipidemia of the present invention, the side effect may be caused by a decrease in coenzyme Q10 (Coenzyme Q10).

Meanwhile, the pharmaceutical composition for treating or preventing hyperlipidemia of the present invention may further comprise a pharmaceutically acceptable carrier, diluent or excipient in addition to the active ingredient. Examples of usable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and one or more selected from among them may be used.

Further, in the case of a pharmaceutical composition for treating or preventing hyperlipidemia, it may further include at least one selected from a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent or an antiseptic agent.

On the other hand, the formulation of the pharmaceutical composition for the treatment or prevention of hyperlipidemia may be in a desirable form depending on the method of use, and may be a method known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal It is preferable to adopt a formulation. Examples of specific formulations include, but are not limited to, PLASTERS, GRANULES, LOTIONS, LINIMENTS, LEMONADES, AROMATIC WATERS, POWDERS, SYRUPS, OPHTHALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS, ), Suspensions, DECOCTIONS, INFUSIONS, OPHTHALMIC SOLUTIONS, TABLETS, SUPPOSITORIES, INJECTIONS, SPIRITS, CATAPLSMA, ), Capsules, CREAMS, TROCHES, TINCTURES, PASTES, PILLS, soft or hard gelatin capsules.

On the other hand, the dosage of the pharmaceutical composition for treating or preventing hyperlipidemia of the present invention is preferably determined in consideration of the administration method, the age, sex, weight, and severity of the disease. For example, the pharmaceutical composition for treating or preventing hyperlipidemia according to the present invention may be administered at least once per day at a dose of 0.00001 to 100 mg / kg (body weight) based on the active ingredient. However, the dosage is only an example and may be changed by a doctor's prescription depending on the condition of the recipient.

On the other hand, the contrary of the present invention (半夏, Pinellia ternata ) refers to perennial herbaceous plants grown in the field, and is also called an instrument. Leaves are 1 ~ 2 in diameter and consist of 3 small leaves. Small leaves are 3 ~ 12 cm in length, 1 ~ 5 cm in width, oval or oval or lanceolate, with flat edges and no hairs on both sides. In one room, the dried beans are mixed with ginger to make them dry, coughing, vomiting, headache, etc.

On the other hand, the above-mentioned Atractylodes macrocephala Koidz), Atractylodes japonica Koidzumi or Atractylodes macrocephala Koidzumi), which means that the function of the stomach is fragile, resulting in a noticeable feeling of malaise. The face is yellow, the stool is thin, the diarrhea is good, the water is stagnant and the whole body is swollen Helps to excrete moisture when not digested. It is also used for boobs, coughs, clear sputum due to accumulation of water and wetness in the spleen. It is also used for the sweating of the skin on the skin due to weakness (脾气) .

On the other hand, the invention of the Pegasus (天麻, Gastrodia elata ) is effective for the treatment of headache, vertigo, and numbness of the extremities by the efficacy of giant wind, seismic cramps, and paralyzes.祛痰 epistaxis) is known to be effective in treating headache and dizziness.

On the other hand, the dermis (Citrus unshiu peel) of the present invention means a mature perilla of citrus unshiu Markovich or a relative plant of the same origin, and it is said that the longer the better, the better the redness of the color. Skin, and dermis. The dermis is known to relieve stiffness and strengthen the function of the spleen, treating abdominal pains, trimming, vomiting, nausea, dyspepsia, sluggishness, lingering symptoms, and thin stools.

On the other hand, the above-mentioned Poria cocos of the present invention is a kind of fungi, which is sclerot belonging to mushroom and Wolfporia. In the natural world, bamboo shoots can be formed into painted fruiting bodies through the same process as ordinary mushrooms, or mycelium can grow to form sclerotia.

On the other hand, the Crataegus of the present invention (山査, Crataegus pinnatifida ) has the effect of digesting the food, eliminating the accumulation, activating the blood, and eliminating the blood. In addition, it is known that it is useful for post-natal post labor pain (芎芎 芎) if it is combined with 芎. (川芎) here.

On the other hand, the huiryeom (Siegesbeckia of the invention pubescens Makino) is said to have been attached because the smell of the grass is similar to pigs and has a spicy and shooty flavor. There is also a name called 猪 膏, which is also named because of the smell. The other names, 虎 膏 and 狗 膏, are said to have been used because they were used to cure tigers or dog bites. When young sprouts are cooked and dipped in water, the bitter taste disappears. Because it is eaten with oil and salt,

On the other hand, the Coptis japonica Makino of the present invention has an effect of antifungal and antipyretic effect due to the efficacy of saponin detoxification and cleansing and conditioning, It is known that the efficacy of the 祛祛濕,, 경 경絡),,,.................................................................................................................................................................................................................................................

The composition of the present invention includes an extract of a medicament containing a mixture of a herbal composition, a herbal composition, a chimpanzee, a dermis, a bamboo shoot, angiotensin and angiotensin converting enzyme (ACE), and reduces the amount of aspartate aminotransferase (AST) to inhibit the side effects of statins.

Brief Description of the Drawings Figure 1 shows the effect of statins on the inhibition of the action of hydroxymethylglutaryl (HMG) -CoA reductase.
FIG. 2 is a graph showing the effect of an extract ('HMC05') on the coenzyme Q10 in the serum of Spontaneously hypertensive rats (SHR), which is a mixture of Bacillus thuringiensis, Bacillus thuringiensis, Dermis, It is a graph showing the influence.
FIG. 3 is a graph showing the effect of an extract ('HMC05') of a medicinal herb which has been mixed with the extracts of Bacillus thuringiensis, Bacillus thuringiensis, Dermatophytes, Bacillus thuringiensis, Bacillus thuringiensis, and Bacillus thuringiensis on coenzyme Q10 in plasma of spontaneously hypertensive rats.
FIG. 4 is a graph showing the effect of the mixed medicinal herb extract ('HMC05') on angiotensin II in the plasma of spontaneously hypertensive rats.
FIG. 5 is a graph showing the effect of mixed medicinal herb extract ('HMC05') on angiotensin converting enzyme (ACE) in the serum of spontaneously hypertensive rats.
FIG. 6 is a graph showing the effect of mixed medicinal herb extract ('HMC05') on hepatocellular enzyme (AST) in the serum of spontaneously hypertensive rats.
FIG. 7 is a graph showing the effect of the mixed medicinal herb extract ('HMC05') on angiotensin converting enzyme (ACE) in the kidney of spontaneously hypertensive rats.
8 is a graph showing the effect of the mixed medicinal extract ('HMC05') on the angiotensin converting enzyme (ACE) in the heart of spontaneously hypertensive rats.
FIG. 9 is a graph showing the effect of mixed medicinal herb extract ('HMC05') on heart weight of spontaneously hypertensive rats.

The present invention suppresses side effects caused by inhibiting the action of hydroxymethylglutaryl (HMG) -CoA reductase, which is an enzyme that produces cholesterol in the liver, as a therapeutic agent for hyperlipidemia (see FIG. 1) .

When statins interfere with the action of (HMG) -CoA reductase in the liver, coenzyme Q10 (coenzyme Q10) produced by the action of (HMG) -CoA reductase is reduced (Reference 1: 10-1048032, Identification No. [0005]), a decrease in coenzyme Q10 causes muscle damage, kidney damage, heart and liver damage, diabetes and hypertension.

The decrease in coenzyme Q10 affects muscle damage is confirmed by reference 2 (Samar O. El-Ganainya et al., Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model, Toxicology 359-360. And the increase in coenzyme Q10 reduces cardiac damage, through reference 3 (Anita Ayer et al., CoQ10 Function and Role in Heart Failure and Ischemic Heart Disease, Annu Rev Nutr. 2015; 35: 175-213) Can be confirmed.

In addition, the increase in coenzyme Q10 affects the improvement of hypertension through the use of reference 4 (Langsjoen P et al., Treatment of essential hypertension with coenzyme Q10, Mol Aspects Med. 1994; 15 Suppl: S265-72) .

Meanwhile, in the present invention, an extract of a medicament containing a mixture of Bacillus thuringiensis, Bacillus thuringiensis, Bacillus subtilis, Bacillus thuringiensis, Bacillus thuringiensis, Bacillus thuringiensis, and Bacillus thuringiensis is used to increase the amount of coenzyme Q10 (Coenzyme Q10) .

In the present invention, one of the symptoms caused by statin ingestion is muscle damage, kidney damage, heart and liver damage, diabetes, and hypertension. In the present invention, a hypertensive rat is used as an experimental subject and angiotensin ), Angiotensin converting enzyme (ACE) and hepatocellular enzyme (AST), and to inhibit hypertension due to side effects of statins. We also investigated the inhibitory effect of statins on cardiac hypertrophy.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.

[ Example  One: Inferiority , Baekseong, Chunma, Dermis, Bokryeong, Sansa, Celebration  And Hwangryeon  Preparation of Extracts of Mixed Medicaments]

15 grams of semi-summer, 20 grams of white powder, 10 grams of chunmein, 10 grams of dermis, 15 grams of bamboo shoots, 15 grams of mountain gardens, 15 grams of comedones, And 15 g of Hwangryun were mixed and then heated at 100 캜 for 1 hour and 30 minutes.

After the electrolytic bath was completed, the extract was filtered with 1 탆 filter paper, concentrated under reduced pressure in a vacuum concentrator (degree of vacuum 60-70 cmHg) and heated in a sterilization tank (100 ° C) for 1 hour.

Thereafter, the mixture was allowed to stand for one day and heated again for 1 hour to obtain a mixed medicinal extract. This was dried (obtained in a yield of 51.5%) and used as "HMC05" in the following experimental example.

[ Experimental Example  One: Inferiority , Baekseong, Chunma, Dermis, Bokryeong, Sansa, Celebration  And Hwangryeon  Measurement of inhibitory effect of statin adverse effects on mixed medicinal herb extracts]

In this experiment, the coenzyme Q10, angiotensin II, angiotensin converting enzyme (ACE) and hepatocyte enzyme (AST) of the rat suffering from hypertension, which is one of side effects of statins, To investigate the effects of extracts of Bacillus thuringiensis, Bacillus sp.

The rats used were Spontaneously hypertensive rats (SHR) at 6 weeks of age and weighing 200 to 220 g, and male rats weighing 200 to 220 g at 6 weeks of age without hypertension (Wister kyoto rat) was used.

The experimental rats in each group were fed a sufficient amount of water while freezing the solid feed until the day of the experiment.

The mice were adapted to the laboratory environment for 1 week by setting the room temperature to 22 ± 2 ℃, the relative humidity of 50 ± 10%, the lighting time of 12 hours (07:00 ~ 19:00) and the illumination of 150 ~ 300 Lux. Were used for the experiment. The experiment was conducted in compliance with the animal experiment ethics regulations of the Food and Drug Administration.

The composition and amount of solid feed used in this experiment are shown in Table 1 below.

ingredient Content (% by weight) Crude protein 22.1% or more Crude fat 3.5% or more Crude fiber 5.0% or less Views min Less than 8.0% calcium 0.6% or more sign 0.4% or more

('HMC05'), a mixture of Bacillus thuringiensis, Bacillus thuringiensis, Dermatophyte, Bacillus thuringiensis, Bacillus thuringiensis, Bacillus thuringiensis and Rhodiola, prepared in Example 1, was administered to Spontaneously hypertensive rats (SHR ) &Apos;. < / RTI >

Thereafter, coenzyme Q10, angiotensin II (angiotensin II), angiotensin converting enzyme (ACE), and angiotensin converting enzyme (ACE) in each blood of spontaneously hypertensive rats administered with mixed medicinal herb extract ('HMC05') and spontaneously hypertensive rats and control ) And hepatocyte enzyme (AST) were measured.

Angiotensin converting enzyme (ACE) was also measured in rat kidney and heart.

As a result, it was confirmed that coenzyme Q10 (coenzyme 10) was increased in the serum and plasma of spontaneously hypertensive rats administered with the mixed medicinal extract ('HMC05') (Figs. 2 to 3), and angiotensin II , Angiotensin converting enzyme (ACE) and hepatocyte enzyme (AST) were decreased (Figs. 4 to 6).

However, the coenzyme Q10 and angiotensin converting enzyme (ACE) decreased in proportion to the concentration of the mixed drug extract ('HMC05') and the angiotensin II and hepatic enzyme (AST) mg / kg. In addition, it was confirmed that angiotensin converting enzyme (ACE) decreases in the kidney and heart of spontaneously hypertensive rats administered with the mixed medicinal extract ('HMC05') (FIGS. 7 to 8).

From these results, it can be seen that the composition of the present invention contains an extract of a medicinal substance in which a mixture of Bacillus thuringiensis, Bacillus thuringiensis, Dermis, Bacillus thuringiensis, Bacillus thuringiensis, It is confirmed that the effect of reducing the amount of angiotensin and angiotensin converting enzyme (ACE), which are related markers, and the amount of aspartate aminotransferase (AST) there was.

[ Experimental Example  2: Inferiority , Baekseong, Chunma, Dermis, Bokryeong, Sansa, Celebration  And Hwangryeon  Effect of mixed medicinal herb extract on heart hypertrophy]

In this Experimental Example, by extracting the extract of the medicinal materials prepared in Example 1, which is a mixture of anti-hypertrophy, hypercholesterolemia, dermis, bacillus, And to measure the effects of these factors.

For this, as a control group, spontaneously hypertensive rats (SHR), mixed medicinal extracts ('HMC05') orally administered hypertensive rats (SHR) orally administered with the mixed medicinal extract ('HMC05' Was used to dissect the used WKY (Wister kyoto rat) to measure the heart weight, the length of the tibia, and the weight of the lung. At this time, the ratio of the cardiac weight / tibia length is a marker showing increased cardiac mass due to cardiac hypertrophy.

As a result, the cardiac weight / tibia length of spontaneously hypertensive rat (SHR) was higher than that of control group (WKY), and when mixed drug extract ('HMC05' And the weight of the test specimens decreased. However, the weight of the lungs did not differ greatly.

From this, it was confirmed that 'HMC05' suppressed cardiac hypertrophy and suppressed cardiac damage.

[ Example  2: Inferiority , Baekseong, Chunma, Dermis, Bokryeong, Sansa, Celebration  And Hwangryeon  Preparation of Food Composition Containing Extract of Mixed Medicinal Material]

In Example 2, a food composition for inhibiting statin adverse effects was prepared as follows.

(1) Manufacturing of wire

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and then the mixture was prepared into powder having a particle size of 60 mesh by a pulverizer. Black beans, black sesame seeds and perilla seeds were each steamed and dried by known methods, and then power distribution and pulverization were carried out to prepare powder having a particle size of 60 mesh. Thereafter, 30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley, 9% by weight of glutinous rice, 7% by weight of perilla seed, 8% by weight of black soybean, 7% by weight of black sesame, 3% by weight of the extract, 0.5% by weight of Ganoderma lucidum and 0.5% by weight of Rhizobium were mixed with each other.

(2) Production of chewing gum

0.1% by weight of an extract of a medicinal material mixed with 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of fragrance and 2% by weight of water, To prepare chewing gum.

(3) Candy manufacturing

0.1% by weight of an extract of a mixture of 60% by weight of sugar, 39.8% by weight of starch syrup, 0.1% by weight of fragrance and a medicinal ingredient mixed with Pyridianum, Rhizoma, Dermatophyte, .

(4) Manufacturing of biscuits

By weight of starch, 0.77% by weight of glucose, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonia, 0.17% by weight of sodium bicarbonate, 0.16% by weight of sodium bisulfite 1.45 wt% of rice flour, 0.0001 wt% of vitamin B _1, 0.0001 wt% of vitamin B ₂ , 0.04 wt% of milk fractions, 20.6998 wt% of water, 1.16 wt% of whole milk powder, 0.29 wt% , 0.29% by weight of spray salt, and 7.27% by weight of spray oil, and 1% by weight of an extract of a medicinal material mixed with Pepper, Chumma, Dermis,

(5) health drink manufacturing

A mixture of 0.26% by weight of honey, 0.0002% by weight of chitosanic acid amide, 0.0004% by weight of nicotinic acid amide, 0.0001% by weight of riboflavin sodium chloride, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of orthoacetic acid and 98.7362% 1% by weight of an extract of a medicinal herb which is a mixture of Phellinus linteus, Ganoderma lucidum, Dermatophyte, Bacillus thuringiensis, Lycoris sieboldii, Comvitae and Rhodiola was added to prepare a health drink.

(6) Production of sausages

(3 ', 4'-dihydroxyphenyl) glycine was prepared by mixing 65.18% by weight of pork, 25% by weight of chicken meat, 3.5% by weight of starch, 1.7% by weight of soybean protein, 1.62% -Gamma-valerolactone or a derivative thereof in an amount of 1% by weight based on the total weight of the sausage.

(7) Health supplement manufacturing

Spirulina 55% by weight, guar gum enzyme degradation product of 10 wt%, vitamin B ₁ hydrochloride 0.01% by weight vitamin B ₆ hydrochloride 0.01%, DL- methionine, 0.23% by weight, 0.7% by weight magnesium stearate, 22.2 wt% lactose and corn starch 1.85 10% by weight of an extract of a medicinal material mixed with a mixture of a carbohydrate, a carbohydrate, a carbohydrate, a dandelion, a dandelion, a bamboo shoot,

[ Example  3: Inferiority , Baekseong, Chunma, Dermis, Bokryeong, Sansa, Celebration  And Hwangryeon  Preparation of a pharmaceutical composition containing an extract of a mixed medicament]

In Example 3, a pharmaceutical composition for inhibiting statin adverse effects was prepared as follows.

(1) Manufacture of powders

2 g of lactose was mixed with 1 g of an extract of a medicinal herb which was prepared by mixing the herbicidal compositions of the present invention,

(2) Preparation of tablets

100 mg of corn starch, 100 mg of lactose, or 2 mg of magnesium stearate were mixed and then tableted according to a conventional tablet preparation method. Tablets were prepared.

(3) Manufacture of capsules

100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed and then filled in gelatin capsules to prepare capsules. The capsules were prepared by mixing 100 mg of the extract of Bacillus thuringiensis, Respectively.

Claims (14)

It contains an extract of a medicinal herb which is a mixture of semi-summer, white liquor, chunmei, dermis, bamboo shoot, mountain scrub, , And suppresses side effects due to statin use.
The method according to claim 1,
The food composition may contain,
0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of dermis, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, And 2 parts by weight of an extract of the medicinal substance.
Wherein the composition comprises at least one or more of the following ingredients: anhydrous extract, alfalfa extract, Ganoderma lucidum extract, dermatophyte extract, ginseng extract, Crassulaceae extract, Comvita extract and Rhodiola extract and inhibits adverse effects due to use of statin.
The method of claim 3,
The food composition may contain,
0.5 to 2 parts by weight of an extract of Chionrae, 0.5 to 2 parts by weight of an extract, 0.5 to 2 parts by weight of a dandruff extract, 0.5 to 2 parts by weight of a dandelion extract, 0.5 to 2 parts by weight of a sea tangle extract, 2 < / RTI > parts by weight of the extract and 0.5 to 2 parts by weight of the extract.
The method according to claim 1 or 3,
The side effect,
Diabetes, hypertension, hepatotoxicity, and myopathy. ≪ RTI ID = 0.0 > 21. < / RTI >
Wherein the pharmaceutical composition comprises an extract of a medicinal substance mixed with an antiperspirant, an extract, a dermatophyte, a dermis, a bamboo shoot, a sorghum, a japonica, and a chrysanthemum, and inhibits adverse effects due to the use of statin.
The method according to claim 6,
The pharmaceutical composition may contain,
0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of dermis, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, And 2 parts by weight of a pharmaceutical composition.
The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition contains an anti-depressant extract, a chrysanthemum extract, a chewing gum extract, a dermis extract, a bamboo extract, a horseradish extract, a royal jelly extract and a chrysanthemum extract.
9. The method of claim 8,
The pharmaceutical composition may contain,
0.5 to 2 parts by weight of an extract of Chionrae, 0.5 to 2 parts by weight of an extract, 0.5 to 2 parts by weight of a dandruff extract, 0.5 to 2 parts by weight of a dandelion extract, 0.5 to 2 parts by weight of a sea tangle extract, 2 < / RTI > parts by weight of the extract and 0.5 to 2 parts by weight of the extract.
9. The method according to claim 6 or 8,
The side effect,
Diabetes, hypertension, hepatotoxicity, and myopathy. ≪ RTI ID = 0.0 > 18. < / RTI >
A pharmaceutical composition for the treatment or prevention of hyperlipidemia comprising statin,
The pharmaceutical composition may contain,
Wherein the pharmaceutical composition further comprises an extract of a medicament which is mixed with the extract, the extract, the ginseng extract, the ginseng extract, the ginseng extract,
12. The method of claim 11,
The pharmaceutical composition may contain,
0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of dermis, 0.5 to 2 parts by weight of honeycomb, 0.5 to 2 parts by weight of honeycomb, And 2 parts by weight of a pharmaceutical composition.
A pharmaceutical composition for the treatment or prevention of hyperlipidemia comprising statin,
The pharmaceutical composition may contain,
Wherein the extract further comprises an extract of Liliaceae, Liliaceae extract, Liliaceae extract, Liliaceae extract, Dermatophyte extract, Liliaceae extract, Crassulaceae extract, Comida extract and Rhodiola extract.
14. The method of claim 13,
The pharmaceutical composition may contain,
0.5 to 2 parts by weight of an extract of Chionrae, 0.5 to 2 parts by weight of an extract, 0.5 to 2 parts by weight of a dandruff extract, 0.5 to 2 parts by weight of a dandelion extract, 0.5 to 2 parts by weight of a sea tangle extract, 2 < / RTI > parts by weight of the extract and 0.5 to 2 parts by weight of the extract.

Images